These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 112806)
1. [Virulence and the antigens of Pseudomonas aeruginosa]. Stanislavskiĭ ES; Kolker II Zh Mikrobiol Epidemiol Immunobiol; 1979 Jul; (7):16-23. PubMed ID: 112806 [No Abstract] [Full Text] [Related]
2. Antigens of Pseudomonas aeruginosa and their use in immunoprophylaxis and immunotherapy. Stanislavsky ES; Dmitriev BA; Lányi B; Joó I Acta Microbiol Hung; 1985; 32(1):3-37. PubMed ID: 2412389 [No Abstract] [Full Text] [Related]
3. Biochemical and genetic aspects of Pseudomonas aeruginosa virulence. Lory S; Tai PC Curr Top Microbiol Immunol; 1985; 118():53-69. PubMed ID: 2414071 [No Abstract] [Full Text] [Related]
6. [Cell-free Pseudomonas vaccine. II. Isolation and immunological properties of protective antigens of Pseudomonas aeruginosa]. Stanislavskiĭ ES; Palkina NA; Bulk VF; Zhvanetskaia MI; Chekan LV Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):37-40. PubMed ID: 6797158 [No Abstract] [Full Text] [Related]
7. [An immunological study of the cell wall proteins of Pseudomonas aeruginosa]. Makarenko TA; Stanislavskiĭ ES Zh Mikrobiol Epidemiol Immunobiol; 1996; (2):7-9. PubMed ID: 8701662 [TBL] [Abstract][Full Text] [Related]
8. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations. Holder IA; Naglich JG J Trauma; 1986 Feb; 26(2):118-22. PubMed ID: 2418208 [TBL] [Abstract][Full Text] [Related]
9. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection. Montie TC; Drake D; Sellin H; Slater O; Edmonds S Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785 [No Abstract] [Full Text] [Related]
10. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine]. Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956 [No Abstract] [Full Text] [Related]
11. An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates. Li L; Ledizet M; Kar K; Koski RA; Kazmierczak BI Ann Clin Microbiol Antimicrob; 2005 Dec; 4():22. PubMed ID: 16375761 [TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa exotoxin A. Pollack M N Engl J Med; 1980 Jun; 302(24):1360-2. PubMed ID: 6769039 [No Abstract] [Full Text] [Related]
13. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey). Joó I; Stanislavskii ES J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316 [TBL] [Abstract][Full Text] [Related]
14. [Immunoprophylaxis and immunotherapy of infection caused by Pseudomonas aeruginosa: research results and prospects]. Stanislavskiĭ ES; Joó I Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):22-31. PubMed ID: 6414198 [No Abstract] [Full Text] [Related]
15. Comparative studies on the protective potential of antisera directed against four antigenic preparations from Pseudomonas aeruginosa. Johnston LJ; Syeklocha D Can J Microbiol; 1972 Oct; 18(10):1607-11. PubMed ID: 4628185 [No Abstract] [Full Text] [Related]
19. The role of hemolysin in corneal infections with Pseudomonas aeruginosa. Johnson MK; Allen JH Invest Ophthalmol Vis Sci; 1978 May; 17(5):480-3. PubMed ID: 417045 [TBL] [Abstract][Full Text] [Related]